BRAIDWELL LP portfolio

Latest available portfolio: Q3 2026 · Holdings as of · Filed ·
$2.41BFull value: $2,409,466,201 · USD · 30 Sep 2026
in Form 13F holdings
See latest portfolio changes

Quarterly portfolio filings

Choose a quarter to see holdings and changes. Newer portfolio dates appear first.

Estimated additions and reductions require qualified adjacent-quarter disclosures and use filing-derived prices. A dash means unavailable; these estimates are not actual trade proceeds or costs.

Quarter Holdings SEC-reported value Est. additions Est. reductions Est. net Top Holdings Form Type Accepted by SEC
Q3 2026 88 $2,409,466,201 — — — KOD, CAI, EWTX, ATEC, IRTC 13F-HR 16 Nov 2026, 16:52
Q2 2026 86 $2,703,471,368 — — — CAI, HNGE, GKOS, EWTX, SYRE 13F-HR 14 Aug 2026, 16:22
Q1 2026 88 $2,997,744,331 — — — CAI, GUARDANT HEALTH INC, REPLIGEN CORP, NEOGENOMICS INC, NBIX 13F-HR 15 May 2026, 16:08
Q4 2025 73 $3,126,999,740 — — — CAI, GUARDANT HEALTH INC, EWTX, REPLIGEN CORP, NBIX 13F-HR 17 Feb 2026, 17:12
Q3 2025 73 $3,370,348,920 — — — GUARDANT HEALTH INC, CAI, NOVOCURE LTD, XENE, CGON 13F-HR 14 Nov 2025, 16:07
Q2 2025 55 $2,923,924,032 — — — GUARDANT HEALTH INC, CAI, NBIX, NOVOCURE LTD, XENE 13F-HR 14 Aug 2025, 16:34
Q1 2025 64 $2,844,802,567 — — — GUARDANT HEALTH INC, NOVOCURE LTD, NBIX, LEGN, REPLIGEN CORP 13F-HR 15 May 2025, 16:34
Q4 2024 73 $3,372,652,431 — — — GUARDANT HEALTH INC, BRIDGEBIO PHARMA INC, NOVOCURE LTD, NBIX, REPLIGEN CORP 13F-HR 14 Feb 2025, 16:18
Q3 2024 81 $3,527,985,574 — — — GUARDANT HEALTH INC, BRIDGEBIO PHARMA INC, NOVOCURE LTD, CGON, NUVASIVE INC 13F-HR 14 Nov 2024, 16:22
Q2 2024 75 $3,187,767,909 — — — GUARDANT HEALTH INC, BRIDGEBIO PHARMA INC, NOVOCURE LTD, NUVASIVE INC, NBIX 13F-HR 14 Aug 2024, 16:29
Q1 2024 70 $3,102,773,641 — — — GUARDANT HEALTH INC, BRIDGEBIO PHARMA INC, EXACT SCIENCES CORP, NOVOCURE LTD, APGE 13F-HR 15 May 2024, 16:26
Q4 2023 72 $2,722,670,757 — — — GUARDANT HEALTH INC, BRIDGEBIO PHARMA INC, ASCENDIS PHARMA A/S, EXACT SCIENCES CORP, NOVOCURE LTD 13F-HR 14 Feb 2024, 16:37
Q3 2023 85 $3,164,360,709 — — — GUARDANT HEALTH INC, NOVOCURE LTD, ASCENDIS PHARMA A/S, EXACT SCIENCES CORP, NANOSTRING TECHNOLOGIES INC 13F-HR 14 Nov 2023, 16:36
Q2 2023 81 $3,060,428,640 — — — GUARDANT HEALTH INC, EXACT SCIENCES CORP, NOVOCURE LTD, NANOSTRING TECHNOLOGIES INC, ASCENDIS PHARMA A/S 13F-HR 14 Aug 2023, 16:29
Q1 2023 81 $2,924,706,963 — — — GUARDANT HEALTH INC, EXACT SCIENCES CORP, NANOSTRING TECHNOLOGIES INC, NOVOCURE LTD, ALPHATEC HLDGS INC 13F-HR 15 May 2023, 17:18
Q4 2022 88 $2,946,459,579 — — — GUARDANT HEALTH INC, NANOSTRING TECHNOLOGIES INC, NOVOCURE LTD, EXACT SCIENCES CORP, ALPHATEC HLDGS INC 13F-HR 14 Feb 2023, 16:27

Showing 1-16 of 16 filings.

Manager details and filing context
Latest 13F filing
Q3 2026 - 16 Nov 2026
Latest reported 13F value
$2,409,466,201
Largest 13F holdings
KOD CAI EWTX ATEC IRTC ALPHATEC HLDGS INC HNGE SYRE XENE NEO GKOS VERA
+8 moreTMDX ISRG AVAH NBIX DNTH BTSG GENB MRVI
Manager location
Stamford, CT
Holdings Value
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .